Skip to content

Ardelyx ARDX Short-Term Investments

Short-Term Investments at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$1.05B+40.1%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$623.44M-23.4%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+79.5%
Enterprise value$1.71B+74.8%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's short-term investments?
Ardelyx (ARDX) reported short-term investments of $206.87M in Q1 2026.
How has Ardelyx's short-term investments changed year-over-year?
Ardelyx's short-term investments increased by 13.0% year-over-year, from $183.14M to $206.87M.
What is the long-term trend for Ardelyx's short-term investments?
Over 5 years (2020 to 2025), Ardelyx's short-term investments has grown at a 15.6% compound annual growth rate (CAGR), from $95.45M to $196.69M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.